Endometriosis-associated cancer: modern aspects of etiopathogenesis, treatment and rehabilitation

Full Text:


Aim: to analyze current literature sources on endometriosis-associated cancer (ЕАС) in gynecology.

Materials and Methods. We searched for publications in the international scientific databases: eLibrary, Google Scholar, ScienceDirect, Cochrane Library, PubMed/MEDLINE and clinical research registries. For this systematic analysis, only full-text publications were used. We evaluated the reliability of evidence and the methodological quality of the studies. The data on the modern approach to the therapy and rehabilitation of women with external genital endometriosis (EGE) are presented. Search terms for publications in Russian and English were used: «endometriosis», «endometriosis-associated ovarian neoplasia», «oncology», «rehabilitation».

Results. Despite the fact that EGE is considered a benign disease, there is a risk for its malignant transformation. However, the pathogenesis and pathomorphological mechanisms of ЕАС are not yet fully understood.

Conclusion. Active management of the rehabilitation period for women with EGE provides an opportunity for early diagnosing recurrences that will provide early diagnostics ovarian ЕАС and improve the main indicators of the quality of life for such patients.

About the Authors

E. Begovich
Sechenov University
Russian Federation

Evana Begovich – MD, Postgraduate Student, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children's Health

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

A. G. Solopova
Sechenov University
Russian Federation

Antonina G. Solopova – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children's Health

Scopus Author ID: 6505479504

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

V. O. Bitsadze
Sechenov University
Russian Federation

Viktoriya O. Bitsadze – MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

Scopus Author ID: 6506003478; Researcher ID: F-8409-2017

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

S. V. Khlopkova
Vorokhobov City Clinical Hospital № 67, Moscow Healthcare Department
Russian Federation

Svetlana V. Khlopkova – MD, Obstetrician-Gynecologist of the Highest Qualification Category, Head of the Department of Gynecology

2/44 Salyama Adilya Str., Moscow 123423

E. A. Orudzhova
Vorokhobov City Clinical Hospital № 67, Moscow Healthcare Department
Russian Federation

Esmira A. Orudzhova – MD, Head of Antenatal Outpatient Care Center, Maternity Hospital № 1 – Branch of Vorokhobov City Clinical Hospital № 67

2/44 Salyama Adilya Str., Moscow 123423


1. Efimenko T.O. The structure, nature and intensity of pain in various forms of external genital endometriosis. [Struktura, harakter i intensivnost' bolevogo sindroma pri razlichnyh formah naruzhnogo genital'nogo endometrioza]. Zhurnal akusherstva i zhenskih boleznej. 2016;65(2):24–30. (In Russ.).

2. Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N Engl J Med. 2020;382(13):1244–56.

3. Mishra V.V., Bandwal P., Agarwal R., Aggarwal R. Prevalence, clinical and laparoscopic features of endometriosis among infertile women. J Obstet Gynaecol India. 2017;67(3):208–12.

4. Kok V.C., Tsai H.J., Su C.F. et al. The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: A population-based study. Int J Gynecol Cancer. 2015;25(6):968–76.

5. Mogensen J.B., Kjær S.K., Mellemkjær L. et al. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. Gynecol Oncol. 2016;143(1):87–92.

6. Zondervan K.T., Becker C.M., Koga K. et al. Endometriosis. Nat Rev Dis Primers. 2018;19;4(1):9.

7. Borrelli G.M., Abrao M.S., Taube E.T. et al. Immunohistochemical investigation of metastasis-related chemokines in deep-infiltrating endometriosis and compromised pelvic sentinel lymph nodes. Reprod Sci. 2015;22(12):1632–42.

8. Borrelli G.M., Abrao M.S., Taube E.T. et al. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. Mol Hum Reprod. 2016;22(5):329–37.

9. Wang Q., Wang L., Yali L. et al. Expression and significance of ARID1A mRNA in endometriosis-associated ovarian cancer. J BUON. 2017;22(5):1314–21.

10. Dinkelspiel H.E., Matrai C., Pauk S. et al. Does the presence of endometriosis affect prognosis of ovarian cancer? Cancer Invest. 2016;34(3):148–54.

11. Brilhante A.V.M., Augusto K.L., Portela M.C. et al. Endometriosis and ovarian cancer: an integrative review (endometriosis and ovarian cancer). Asian Pac J Cancer Prev. 2017;18(1):11–6.

12. Álvarez-Salvago F., Lara-Ramos A., Cantarero-Villanueva I. et al. Chronic fatigue, physical impairments and quality of life in women with endometriosis: a case-control study. Int J Environ Res Public Health. 2020;17(10):3610.

13. Oza A.M., Cook A.D., Pfisterer J. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.

14. Matias-Guiu X., Stewart J.R.C. Endometriosis-associated ovarian neoplasia. Pathology. 2018;50(2):190–204.

15. Wilbur M.A., Shih I.M., Segars J.H., Fader A.N. Cancer implications for patients with endometriosis. Semin Reprod Med. 2017;35(1):110–6.

16. Krawczyk N., Banys-Paluchowski M., Schmidt D. et al. Endometriosisassociated malignancy. Geburtshilfe Frauenheilkd. 2016;76(2):176–81.

17. Othman E.R., Markeb A.A., Khashbah M.Y. Markers of local and systemic estrogen metabolism in endometriosis. Reprod Sci. 2000;28(4):1001–11.

18. Herreros-Villanueva M., Chen C.C., Tsai E.M., Er T.K. Endometriosisassociated ovarian cancer: what have we learned so far? Clin Chim Acta. 2019;493:63–72.

19. Ito F., Yamada Y., Shigemitsu A. et al. Role of oxidative stress in epigenetic modification in endometriosis. Reprod Sci. 2017;24(11):1493– 502.

20. Hout M.E., Dos Santos L., Hamaï A., Mehrpour M. A promising new approach to cancer therapy: targeting iron metabolism in cancer stem cells. Semin Cancer Biol. 2018;53:125–38.

21. Sheikhvatan M., Chaichian S., Moazzami B. A systematic review and bioinformatics study on genes and micro-RNAs involving the transformation of endometriosis into ovarian cancer. Microrna. 2020;9(2):101–11.

22. Su K.M., Wang P.H., Yu M.H. et al. The recent progress and therapy in endometriosis-associated ovarian cancer. J Chin Med Assoc. 2020;83(3):227–32.

23. Lim M.C., Chang S.J., Yoo H.J. et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol. 2017;35(15):5520.

24. Koole S.N., van Driel W.J., Sonke G.S. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on. Cancer. 2019;125(24):4587–93.

25. Bevers T.B., Ward J.H., Ahrendt G.M. et al. Breast cancer risk reduction. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines, Version 1.2020 – May 29, 2020). National Comprehensive Cancer Network®, 2020. 64 p. Available at:

26. Chan J.K., Brady M.F., Penson R.T. et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374(8):738–48.

27. Ray-Coquard I., Cibula D., Mirza M.R. et al. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 2020;146(2):439–48.

28. Coleman R.L., Brady M.F., Herzog T.J. et al. Bevacizumab and paclitaxel– carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.

29. Ledermann J.A. First-line treatment of ovarian cancer: questions and controversies to address. Ther Adv Med Oncol. 2018;10(15):1–8.

30. Matulonis U.A., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Оverall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122(12):1844–52.

31. Solopova A., Vlasina A., Rozanov I., Moskvicheva V. Rehabilitation of patients with borderline ovarian tumors. [Reabilitaciya bol'nyh pogranichnymi opuholyami yaichnikov: sovremennoe videnie problem]. Vrach. 2018;29(8):21–5. (In Russ.).

32. Holt K.A., Jensen P.T., Hansen D.G., Elklit A. Rehabilitation of women with gynaecological cancer: the association between adult attachment, post-traumatic stress disorder and depression. Psychooncology. 2016;25(6):691–8.

33. Cutshall S.M., Cha S.S., Ness S.M. et al. Symptom burden and integrative medicine in cancer survivorship. Support Care Cancer. 2015;23(10):2989–94.

34. Vlasina A.Yu., Idrisova L.E., Solopova A.G. et al. Rehabilitation of oncogynecological patients after antitumor therapy: ways of solution. [Reabilitaciya onkoginekologicheskih bol'nyh posle protivoopuholevoj terapii: puti resheniya]. Obstetrics, Gynecology and Reproduction. 2020;14(1):44–55. (In Russ.).


For citations:

Begovich E., Solopova A.G., Bitsadze V.O., Khlopkova S.V., Orudzhova E.A. Endometriosis-associated cancer: modern aspects of etiopathogenesis, treatment and rehabilitation. Obstetrics, Gynecology and Reproduction. 2021;15(3):287-294. (In Russ.)

Views: 433

ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)